Lepur D., Kutleša M., Baršić B. (2011) *Induced hypothermia in adult community-acquired bacterial meningitis—more than just a possibility?* Journal of Infection, 62 (2). pp. 172-7. ISSN 0163-4453

http://www.elsevier.com/locate/issn/01634453

http://www.sciencedirect.com/science/journal/01634453

http://dx.doi.org/10.1016/j.jinf.2010.10.001

http://medlib.mef.hr/983

University of Zagreb Medical School Repository
http://medlib.mef.hr/
Induced hypothermia in adult community-acquired bacterial meningitis - more than just a possibility?

Dragan Lepur¹, Marko Kutleša¹ and Bruno Baršić¹

Running title: Hypothermia in adult community-acquired bacterial meningitis

Dragan Lepur, MD, PhD, specialist in infectious diseases (corresponding author)
¹Department of Neuroinfections and Intensive Care Medicine
University Hospital for Infectious Diseases “Dr. Fran Mihaljević”
Zagreb 10000, Croatia
Tel.: +385 1 2826 253, +385 1 2754 880
Fax: +385 1 2826 255
E-mail: lepirx@inet.hr
Conflict of interest: none

Marko Kutleša, MD, specialist in infectious diseases
E-mail: marko.kutlescha@gmail.com
Conflict of interest: none

Bruno Baršić, MD, PhD
Professor of Infectious Diseases, Head
E-mail: bbarsic@bfm.hr
Conflict of interest: none

Word count of the text: 1586
Word count of the abstract: 80

Key words: Hypothermia; adult; community-acquired; bacterial meningitis; S.pneumoniae
ABSTRACT

We present case series of adult community-acquired bacterial meningitis treated with hypothermia. The major criteria for therapeutic hypothermia (TH) was impaired carbon dioxide reactivity (CO$_2$R) assessed by Transcranial Doppler (TCD). In patients without temporal acoustic window, minor criteria (optic nerve sheath diameter $\geq 6.0$ mm plus GCS $\leq 8$) were required. According to our, although limited experience, the use of mild hypothermia in selected patients with community-acquired bacterial meningitis accompanied with appropriate monitoring could be a promising treatment tool.
INTRODUCTION

Despite recent advances in antibiotic therapy and critical care, bacterial meningitis continues to impose high rates of morbidity and mortality.\textsuperscript{1-4} Given that bacterial meningitis frequently has associated poor outcomes, new treatment strategies are needed. Of particular interest is therapeutic hypothermia (TH). It has well documented neuroprotective effects and may have a potential use in selected patients with meningitis.\textsuperscript{5,6} We present case series of adult community-acquired bacterial meningitis treated with hypothermia and describe in detail the methods and the rationale for its use.

PATIENTS AND METHODS

In the period between February 2009 and May 2010, ten patients suffering from severe community-acquired bacterial meningitis were treated with hypothermia. All patients were mechanically ventilated. The following treatment protocol was applied in all patients: mild hypothermia (32-34°C) accompanied with daily assessment of cerebrovascular carbon dioxide reactivity (CO\textsubscript{2}R) measured by Transcranial Doppler (TCD) and cerebral perfusion using the lactate-oxygen index (LOI) when available. The LOI was not measured in four patients because of difficult internal vein cannulation. Initial antimicrobial treatment consisted of ceftriaxone alone or in combination with ampicillin. Adjuvant steroid treatment was applied in seven patients.

Despite therapeutic hypothermia, two patients died within 48 hours from admission because of refractory intracranial hypertension. Two patients with severe residual neurological deficits (GOS 2) died after discharge from ICU because of late-onset nosocomial sepsis more than a month upon admission. In the surviving six patients, the ICU stay ranged from 8 to 36 (mean 22) days.

Of these survivors, two had severe and two had moderate residual neurological deficit, the most common being spastic hemiparesis and tetraparesis, respectively. One patient remained paraplegic with urinary incontinence due to severe pneumococcal myelitis. Two of the six survivors had a complete neurological recovery. The patients’ demographic and clinical data are summarized in Tables 1-3.
The hospital Ethics Committee approved the treatment protocol and informed consent was obtained from the relatives of all patients.

**Transcranial Doppler ultrasound (TCD)**

TCD measurement of CO\(_2\) reactivity (CO\(_2\) R) was performed by using a Multidop 4 X (DWL, Sipplingen, Germany) with two 2-MHz pulsed wave probes 1.7 cm in diameter. The software used was TCD-8 for MDX (Version 8.0, Aaslid Rune).

The left and right middle cerebral arteries (MCA) were insonated simultaneously through the temporal bone windows at a depth of 50-55 mm. The probes were secured to the head of the patient with a specially designed spectacle frame that permitted a constant angle of insonation. The mean blood flow velocities (MBFV) were continuously recorded during normal ventilation and during interventions (induced hypercapnia, norepinephrine infusion and hyperventilation). CO\(_2\) reactivity (CO\(_2\) R) was assessed using the breath-holding method (disconnection from the ventilator for 30 seconds in a deep sedated and relaxed patient). The breath-holding index (BHI) was calculated by dividing the percentage of MBFV increase during breath holding by the time (in seconds) of apnea. The normal range of BHI is 1.03 – 1.65.\(^7\)

**Optic nerve sheath diameter (ONSD)**

ONSD measurements were made using a B-scan ultrasound with a 10 MHz linear probe (Accuson CV70, Siemens Medical Solutions Inc., WA, USA) before and during the induced hypothermia. Optic nerve sheath diameter has been shown to be a very reliable measure of intracranial pressure (ICP). In adults ONSD greater than 5 mm correlated with a mean cerebrospinal fluid (CSF) pressure of 30 mmHg (elevated).\(^8,9\)

**Jugular bulb oximetry**

The jugular bulb catheter placement offers an opportunity for the measurement of S\(\text{JO}_2\) and calculation of lactate-oxygen index (LOI) using paired arterial and venous blood samples. The measurements were made daily during the period of hypothermia. Desaturation of jugular bulb venous blood (S\(\text{JO}_2\) < 55%) with increased cerebral lactate-oxygen index (LOI > 0.08) [derived from
arterio-jugular venous oxygen content difference (AJVDO₂) and arterio-jugular venous lactate concentration difference (AVDL) are reliable markers of cerebral hypoperfusion. Furthermore, increased SjO₂ (>75%) and LOI with decreased AJVDO₂ could be ominous signs of extreme intracranial hypertension and commonly represent a preterminal event.

**Hypothermia**

We used an internal protocol designed to achieve mild hypothermia (rectal temperature of 32-34°C). Hypothermia was induced by intravenous infusion of cold (+4°C - +8°C) isotonic saline (2000 ml/1 h) and maintained with continuous veno-venous hemofiltration (CVVHF) by using a Prismaflex (Gambro Dasco S.p.A, Medolla, Italy) machine for 72 – 96 hours. The blood flow rate was set to 150 ml/min, ultrafiltration rate (UFR) to zero ml/h and the replacement solution rate was set to 2000 ml/h. Enoxaparin was used for anticoagulation of the circuit.

**DISCUSSION**

While hypothermia has already been used for neuroprotection in a variety of neurological and non-neurological conditions, this method has been exceptionally applied to the treatment of central nervous system infections. Other adjunctive treatment options, such as the use of corticosteroids, despite their beneficial effects in majority of patients have not substantially changed disease outcomes among patients with most severe pneumococcal meningitis.

Common neurological sequelae in survivors of bacterial meningitis may result from neuronal damage, ischemic encephalopathy or ischemic stroke. In our opinion, current therapies do not adequately address the underlying pathophysiology leading to neurologic damage associated with bacterial meningitis. Current treatments are frequently aimed at reducing intracranial pressure and depend on cerebral vasoreactivity. In severe bacterial meningitis, however, cerebral blood flow (CBF) autoregulation is often damaged. Furthermore, cerebral metabolic oxygen demand (CMRO₂) and CBF coupling is frequently disrupted and leads to multisegmental hypoperfusion or hyperemia. The use of mannitol in patients with impaired cerebral arterioles carbon dioxide reactivity (CO₂R) carries the risk for paradoxical aggravation of brain edema because of possible mannitol leakage into the brain tissue. Therefore, the administration of mannitol should be discouraged in such patients. In
addition, the appropriate monitoring of cerebral perfusion pressure (CPP), intracranial pressure (ICP), cerebral oxygen demand, consumption and extraction in these patients is necessary.

The effects of mild hypothermia may target the pathophysiological mechanisms that are in effect during bacterial meningitis because most of them are temperature dependent.\textsuperscript{20,21}

Hypothermia results in neuroprotection through a variety of mechanisms. Decreased body temperature causes reduced production of reactive oxygen and nitrogen species, inhibition of the neuroexcitatory cascade, a reduction in proinflammatory cytokine level, maintenance of blood-brain barrier integrity, decreased intracranial pressure, and finally decreased neuronal apoptosis.\textsuperscript{22-28}

Additionally, adverse events are noted to be rare. When those events occur, they are typically minor.\textsuperscript{5}

According to our framework, the selection of patients for induced hypothermia is primarily based on cerebral arterioles CO\textsubscript{2} reactivity. The criteria for therapeutic hypothermia are GCS \textless 8 accompanied with optic nerve sheath diameter (ONSD) > 6.0 mm if the temporal acoustic window is absent and cerebral vasoreactivity cannot be assessed.

Because of strong correlation of BHI with the severity (particularly with GCS score) and the outcome of the disease, we defined the BHI level of \textless 0.86 as inclusion criteria for hypothermia. Chemoregulation in our patients was severely impaired or completely absent.

We believe that marked reduction of CO\textsubscript{2} reactivity, measured by TCD, accompanied with increased ONSD and altered mental status (GCS \textless 8 ) reliably select patients who are candidates for urgent hypothermia induction. In patients with preserved CO\textsubscript{2} reactivity, the use of hypothermia probably would not yield additional benefit when compared to the standard treatment regimen. The mortality rate in patients with bacterial meningitis and preserved vasoreactivity treated with standard regimen regardless of disease severity was zero (0/14) compared with 25% (5/20) in patients with impaired vasoreactivity (unpublished data).

In all patients with jugular bulb catheter the measurements showed cerebral perfusion impairment (increased LOI) (Table 3). Vasopressors were used to support cerebral perfusion pressure (CPP). Low doses of norepinephrine infusion in addition to hypothermia were sufficient to significantly improve the MBFV and LOI without significant systemic hypertension. A marked reduction in ONSD during hypothermia was also noted (Table 3).

With respect to disease severity, the outcome of our patients was generally satisfactory (Table 1). If the standard treatment regimen had been applied the disease would likely
have been fatal. At admission, one patient had TCD signs of cerebral circulatory arrest while the others were elderly and had severe global cerebral hypoperfusion. The mortality rate in such patients reaches 69%.³

While lowering of body temperature may take several hours in pyretic patients, CVVHF allows the maintenance of a stable body temperature. Our patients had no significant variations in body temperature. In addition, the use of CVVHF allows gradual rewarming of the patient upon recovery.

While there is evidence from animal studies that hypothermia may be beneficial in meningitis and while scarce clinical experience suggests a role for hypothermia, large scale randomized clinical trials are needed.²⁷,²⁸ Inclusion criteria in these trials should be based primarily on the cerebral vasoreactivity status and not on pure randomisation and clinical impression. The use of hypothermia during meningitis is complex, but it likely has a physiologic role in treating bacterial meningitis. It may assist with the reduction in cerebral metabolism, cerebral blood volume (CBV), lowering of the intracranial pressure and suppression of the inflammatory host response allowing maintenance of sufficient cerebral perfusion pressure. Adequate and complete treatment balancing antimicrobial treatment, deep sedation, and controlled cerebral perfusion pressure early in the course of disease is critical. The recovery of CO₂ reactivity cannot be expected before the fourth day of treatment according to our experience. Therefore, we recommended the use of hypothermia (if indicated) as soon as possible and at least during the first three days after presentation.

Despite numerous favorable effects of hypothermia, a more comprehensive approach should be employed. It may be taken into account as an adjunctive therapy that has a role alongside established treatments. According to our findings, hypothermia in carefully selected patients holds promise.
AUTHORS' CONTRIBUTION

All authors wrote, reviewed and revised the article and approved the final version of the manuscript. Dr. Dragan Lepur was primarily responsible for data collection and writing of the manuscript.

ACKNOWLEDGEMENTS

We thank to all staff at the Department of Neuroinfections and Intensive Care Medicine of the University Hospital for Infectious Diseases “Dr. Fran Mihaljević” for their enthusiasm and care. We especially thank the following persons who were personally responsible for renal replacement therapy and hypothermia: Tomislav Krčelić, Vesna Horvat, Biljana Ćoso, Ivana Bačić, Milan Gunčić, Arandel Mihajlović, Jasenka Pauk Majdov, Anica Jasenko and Renata Josipović Mraović.

We thank Ms. Ilana Richman, Mrs. Arijana Pavelić and Mrs. Marija Fijucek for their help in the preparation of the manuscript.

There was no financial support for this study.
REFERENCES


# TABLES

Table 1. Demographic and clinical data of patients with community-acquired bacterial meningitis treated with hypothermia - Part one

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age/sex</th>
<th>Day of disease*</th>
<th>Coexisting conditions</th>
<th>Seizures</th>
<th>Etiology</th>
<th>APACHE II</th>
<th>GCS at admission</th>
<th>GCS at discharge from ICU</th>
<th>GOS</th>
<th>Karnofsky score (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>82/F</td>
<td>1</td>
<td>Otitis</td>
<td>Yes</td>
<td>S. pneumoniae (PSSP)</td>
<td>31</td>
<td>8</td>
<td>15</td>
<td>4</td>
<td>50</td>
</tr>
<tr>
<td>2</td>
<td>63/M</td>
<td>2</td>
<td>Otitis</td>
<td>No</td>
<td>S. pneumoniae (PRSP)</td>
<td>22</td>
<td>4</td>
<td>15</td>
<td>3**</td>
<td>60</td>
</tr>
<tr>
<td>3</td>
<td>41/F</td>
<td>2</td>
<td>Rectal adenocarcinoma</td>
<td>No</td>
<td>S. pneumoniae (PSSP)</td>
<td>32</td>
<td>7</td>
<td>14</td>
<td>4</td>
<td>50</td>
</tr>
<tr>
<td>4</td>
<td>71/F</td>
<td>2</td>
<td>Otitis</td>
<td>No</td>
<td>S. pneumoniae (PSSP)</td>
<td>24</td>
<td>9</td>
<td>NA</td>
<td>2</td>
<td>NA</td>
</tr>
<tr>
<td>5</td>
<td>76/M</td>
<td>2</td>
<td>Acute renal failure</td>
<td>No</td>
<td>E. coli</td>
<td>33</td>
<td>3</td>
<td>NA</td>
<td>1</td>
<td>NA</td>
</tr>
<tr>
<td>6</td>
<td>68/F</td>
<td>2</td>
<td>Immunocompromised, Pneumonia</td>
<td>No</td>
<td>S. pneumoniae (PSSP)</td>
<td>34</td>
<td>3</td>
<td>NA</td>
<td>1</td>
<td>NA</td>
</tr>
<tr>
<td>7</td>
<td>70/M</td>
<td>1</td>
<td>Immunocompromised</td>
<td>No</td>
<td>S. pneumoniae (PSSP)</td>
<td>26</td>
<td>8</td>
<td>15</td>
<td>5</td>
<td>90</td>
</tr>
<tr>
<td>8</td>
<td>75/F</td>
<td>1</td>
<td>Immunocompromised</td>
<td>No</td>
<td>S. pneumoniae (PSSP)</td>
<td>33</td>
<td>4</td>
<td>14</td>
<td>3</td>
<td>40</td>
</tr>
</tbody>
</table>

Legend:
* day of disease on which hypothermia was started
** paraplegia caused by severe myelitis
***Immunocompromised - the use of immunosuppressive drugs or the presence of diabetes mellitus, chronic renal failure or alcoholism
Table 2. Demographic and clinical data of patients with community-acquired bacterial meningitis treated with hypothermia - Part two

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>CSF cell count (cells/mm³)</th>
<th>CSF blood glucose ratio</th>
<th>CSF protein concentration (mg/L)²</th>
<th>CSF lactate concentration (mmol/L)⁶</th>
<th>BHI†</th>
<th>Vasopressor support</th>
<th>Adjuvant dexamethasone treatment</th>
<th>Duration of hypothermia (hours)</th>
<th>Meningitis-related complications</th>
<th>Hypothermia/CVVHF-related complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>36 000</td>
<td>0.5</td>
<td>7 450</td>
<td>18.0</td>
<td>N/A</td>
<td>Yes</td>
<td>Yes</td>
<td>72</td>
<td>none</td>
<td>none</td>
</tr>
<tr>
<td>2</td>
<td>200 000</td>
<td>0.0</td>
<td>12 100</td>
<td>15.9</td>
<td>0.876</td>
<td>Yes</td>
<td>Yes</td>
<td>72</td>
<td>severe myelitis</td>
<td>none</td>
</tr>
<tr>
<td>3</td>
<td>9 216</td>
<td>0.47</td>
<td>1 843</td>
<td>8.6</td>
<td>0.610</td>
<td>No</td>
<td>No</td>
<td>72</td>
<td>none</td>
<td>none</td>
</tr>
<tr>
<td>4</td>
<td>2 560</td>
<td>0.5</td>
<td>9 447</td>
<td>20.4</td>
<td>0.644</td>
<td>No</td>
<td>Yes</td>
<td>72</td>
<td>none</td>
<td>none</td>
</tr>
<tr>
<td>5</td>
<td>1 160</td>
<td>0.03</td>
<td>11 936</td>
<td>25.9</td>
<td>0.350</td>
<td>No</td>
<td>Yes</td>
<td>72</td>
<td>refractory brain edema</td>
<td>none</td>
</tr>
<tr>
<td>6</td>
<td>1 633</td>
<td>0.03</td>
<td>1 780</td>
<td>25.4</td>
<td>0.090</td>
<td>Yes</td>
<td>Yes</td>
<td>72</td>
<td>ischemic stroke</td>
<td>none</td>
</tr>
<tr>
<td>7</td>
<td>12 997</td>
<td>0.39</td>
<td>7 348</td>
<td>18.7</td>
<td>0.210</td>
<td>Yes</td>
<td>Yes</td>
<td>48</td>
<td>refractory brain edema</td>
<td>none</td>
</tr>
<tr>
<td>8</td>
<td>19 200</td>
<td>0.02</td>
<td>7 273</td>
<td>3.42</td>
<td>0.342</td>
<td>Yes</td>
<td>Yes</td>
<td>48</td>
<td>ventriculitis, refractory brain edema</td>
<td>none</td>
</tr>
<tr>
<td>9</td>
<td>4 437</td>
<td>0.23</td>
<td>6 533</td>
<td>19.3</td>
<td>0.495</td>
<td>No</td>
<td>No</td>
<td>96</td>
<td>none</td>
<td>ischemic leukoencephalopathy</td>
</tr>
<tr>
<td>10</td>
<td>4 266</td>
<td>0.0</td>
<td>6 031</td>
<td>12.4</td>
<td>0.0</td>
<td>Yes</td>
<td>No</td>
<td>96</td>
<td>none</td>
<td>ischemic leukoencephalopathy</td>
</tr>
</tbody>
</table>

Legend:

1. Score on Glasgow Outcome Scale - at discharge from ICU  [1(death), 2(vegetative state), 3(severe disability), 4(moderate disability), 5(mild or no disability)]
2. Karnofsky performance score - at discharge from ICU
3. CSF white cell count (normal value: < 5 cells/mm³)
4. CSF-blood glucose ratio (normal value: > 0.4)
5. CSF protein concentration (normal range: 150-450 mg/L)
6. CSF lactate concentration (normal range: 1.58-2.03 mmol/L)
7. Mean breath-holding index - at admission to ICU

† PSSP = penicillin-susceptible Streptococcus pneumoniae
‡ PRSP = penicillin-resistant Streptococcus pneumoniae
Table 3. The brain edema and cerebral perfusion indicators before and during therapeutical hypothermia

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Duration of hypothermia (hours)</th>
<th>0</th>
<th>24</th>
<th>48</th>
<th>72</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BHI&lt;sub&gt;m&lt;/sub&gt;</td>
<td>ONSD&lt;sup&gt;1&lt;/sup&gt; Right</td>
<td>ONSD Left</td>
<td>LOI&lt;sup&gt;2&lt;/sup&gt;</td>
<td>BHI&lt;sub&gt;m&lt;/sub&gt;</td>
</tr>
<tr>
<td>1</td>
<td>6.6</td>
<td>6.8</td>
<td>0.153</td>
<td>-</td>
<td>3.7</td>
</tr>
<tr>
<td>2</td>
<td>0.876</td>
<td>6.6</td>
<td>6.6</td>
<td>-</td>
<td>0.650</td>
</tr>
<tr>
<td>3</td>
<td>0.610</td>
<td>7.4</td>
<td>6.9</td>
<td>0.069</td>
<td>0.584</td>
</tr>
<tr>
<td>4</td>
<td>0.644</td>
<td>6.4</td>
<td>6.0</td>
<td>0.440</td>
<td>0.650</td>
</tr>
<tr>
<td>5</td>
<td>0.350</td>
<td>6.6</td>
<td>6.5</td>
<td>-</td>
<td>0.420</td>
</tr>
<tr>
<td>6</td>
<td>0.080</td>
<td>7.1</td>
<td>7.4</td>
<td>-</td>
<td>0.00</td>
</tr>
<tr>
<td>7</td>
<td>0.210</td>
<td>6.2</td>
<td>6.8</td>
<td>-</td>
<td>0.838</td>
</tr>
<tr>
<td>8</td>
<td>0.342</td>
<td>6.4</td>
<td>6.0</td>
<td>-</td>
<td>0.614</td>
</tr>
<tr>
<td>9</td>
<td>0.495</td>
<td>7.6</td>
<td>7.4</td>
<td>-</td>
<td>0.060</td>
</tr>
<tr>
<td>10</td>
<td>0.000</td>
<td>6.1</td>
<td>6.0</td>
<td>0.074</td>
<td>0.00</td>
</tr>
</tbody>
</table>

Legend:

1 BHI<sub>m</sub> = mean breath holding index (normal range: 1.03 – 1.65)
2 ONSD = optic nerve sheath diameter (normal value < 5.0 mm)
3 LOI = lactate-oxygen index (normal value < 0.03)